An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.
A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.
User Solid_Repeat5382 shared their experience with Pyrilutamide for hair loss, which initially reduced shedding but later lost effectiveness. They plan to switch back to RU58841 and finasteride, while continuing minoxidil and dermapen treatments.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.
The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.
Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.
The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.
The user plans to use RU58841 in the morning and Pyrilutamide in the evening for hair loss treatment, considering replacing Fluridil with Pyrilutamide. They believe Pyrilutamide is effective.
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
The user has been using Pyrilutamide (Pyril) for hair loss for a month alongside finasteride/dutasteride since 2021 but hasn't seen results. They are considering switching to RU58841 due to its many success stories, despite being skeptical about the legitimacy and testing of Pyrilutamide.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.
Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
A 22-year-old is using dutasteride and oral minoxidil for hair loss but is not seeing improvements and is considering adding pyrilumatide and microneedling. Suggestions include trying topical minoxidil, microneedling, and Nizoral shampoo, with a possible future hair transplant.
Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.
Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.
The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.